Table 3.

Change in Volume (mLs) in Defined Facial Regions following Treatment with Teprotumumab

Case	Upper Face (mL)	Midface (mL)	Lower Face (mL)	Temple Right (mL)	Temple Left (mL)	R Orbit (mL)	L Orbit (mL)	Full Face (mL)
1	−1.7	−7.9	−7.2	−0.2	0.5	−2.6	−3.4	−22.5
2	−0.5	2.6	4.2	0.0	0.1	−0.4	−2.6	3.5
3	−1.2	−0.2	−1.6	−0.3	0.0	−2.2	−2.0	−7.4
4	−2.1	−2.3	−0.2	−0.2	−0.1	−4.0	−2.1	−11.0
5	−0.5	3.3	5.5	0.1	0.0	0.4	0.3	9.1
6	−0.1	−5.6	−0.4	−0.3	−1.1	−4.0	−4.7	−16.1
7	−0.9	−0.8	−5.0	−0.3	−1.3	−3.0	−0.1	−11.3
8	−2.6	−4.5	−5.0	−0.5	−0.2	−4.4	−3.3	−20.5
9	0.0	−2.5	0.7	−0.4	−0.2	−1.7	−1.7	−5.7
10	0.0	−8.0	−12.4	−0.9	−0.6	−3.7	−2.2	−27.9
11	−0.5	1.1	−1.4	1.2	1.5	−0.8	−2.5	−1.5
12	0.7	−0.7	−4.1	−0.3	−0.2	−1.1	−0.7	−6.3
13	0.2	4.2	4.1	−0.2	−0.2	−2.3	−2.0	3.9
14	−0.4	1.3	−5.5	−0.1	−0.1	−2.8	−2.8	−10.3
15	−0.4	−1.5	−8.1	−0.1	0.0	−1.0	0.8	−10.5
16	0.0	−2.1	−1.8	−0.1	0.0	−1.1	−1.0	−6.1
17	−0.7	1.7	0.1	0.0	0.0	−1.7	−1.4	−2.1
18	−1.9	−3.8	−8.4	−0.9	−0.2	−1.2	−1.4	−17.8
19	−0.9	−2.8	−3.5	−0.5	−0.4	−0.6	−0.5	−9.0
20	−1.6	−2.3	−5.6	−0.1	0.0	−3.2	−1.3	−14.2
21	−0.3	−2.6	−7.4	−0.3	−0.1	−1.2	−1.1	−13.0
22	−1.5	−1.8	3.1	0.0	−0.4	−1.9	−1.7	−4.3
23	−0.2	−2.2	−1.8	−0.5	−0.5	−0.7	1.0	−4.8
Mean	−0.7	−1.6	−2.7	−0.2	−0.2	−2.0	−1.6	−8.9
SD	0.8	3.2	4.6	0.4	0.5	1.3	1.4	8.7